Market Research Logo

Europe Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Europe Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Europe scleroderma therapeutics market is expected to grow at a high CAGR of 4.9% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Belgium, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2026
Major growing sectors under the market segmentation are as follows:

• In type, systemic scleroderma segment is dominating due to its awareness and treatment availability for its associated diseases. There are many products for this segment on which the clinical trials are going on.

• In treatment type, the drug treatment is growing segment as there are various drugs available in the market for the treatment of scleroderma related complications.

• In end user, hospital has a larger market than other end users because the treatment takes place majorly in hospitals.

Key Market Players

The key market players for Europe scleroderma therapeutics market are listed below:

• Argentis Pharmaceuticals, LLC.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Pfizer Inc.
• Sanofi
• ALLERGAN
• viDA Therapeutics Inc.
• Novartis AG
• Active Biotech AB.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• AstraZeneca
• Daval International Limited
• Others

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Europe Scleroderma Therapeutics Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Europe Scleroderma Therapeutics Market : Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Time Line
2.9 Multivariate Modelling
2.10 Secondary Sources
2.11 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Rising Cases Of Scleroderma
3.1.2 Increasing Access To Medical Insurance In The U.S.
3.1.3 Increasing Merger And Acquisitions
3.2 Restraints
3.2.1 Lack Of Curative Treatment
3.2.2 Stringent Regulations
3.2.3 Counterfeit Products
3.3 Opportunity
3.3.1 Unmet Patient Needs In Systemic Sclerosis
3.4 Challenge
3.4.1 Side Effects Of Drugs
4 Executive Summary
5 Premium Insights
6 Pipeline Products
7 Epidemiology
7.1 History Of Scleroderma:
7.2 Recent Incidence And Prevalence:
7.3 Cause Of Scleroderma:
7.4 Symptoms Of Scleroderma:
7.5 Managing Scleroderma:
8 Europe Scleroderma Therapeutics Market, By Type
8.1 Overview
8.2 Systemic Scleroderma
8.2.1 Limited Cutaneous Systemic Sclerosis Or Crest Syndrome
8.2.2 Diffuse Systemic Sclerosis
8.3 Localized Scleroderma
8.3.1 Morphea
8.3.2 Linear Scleroderma
9 Europe Scleroderma Therapeutics Market, By Treatment Type
9.1 Overview
9.2 Drug Treatment
9.2.1 Drug Treatment, By Type
9.2.1.1 Anti-inflammatory Drugs
9.2.1.2 Immunosuppressants
9.2.1.3 Corticosteroids
9.2.1.4 Proton Pump Inhibitors
9.2.1.5 Calcium Channel Blockers
9.2.1.6 Ace Inhibitors
9.2.1.7 H2 Blockers
9.2.1.8 Pde5 Inhibitors
9.2.1.9 Prostacyclin Analogues
9.2.1.10 Endothelin Receptor Antagonists
9.2.1.11 Chelating Agents (Edathamil Disodium)
9.2.1.12 Others
9.2.2 Drug Treatment, By Distribution Channel
9.2.2.1 Hospital Pharmacy
9.2.2.2 Retail Pharmacy
9.2.2.3 Online Pharmacy
9.2.2.4 Others
9.3 Surgical Treatment
9.4 Therapy
9.4.1 Ultraviolet Light Therapy
9.4.2 Physical Therapy
9.4.3 Others
10 Europe Scleroderma Therapeutics Market, By End User
10.1 Overview
10.2 Hospital
10.3 Specialty Clinics
10.4 Homecare Settings
10.5 Others
11 Europe Scleroderma Therapeutics Market, By Geography
11.1 Europe
11.1.1 U.K.
11.1.2 Germany
11.1.3 France
11.1.4 Spain
11.1.5 Italy
11.1.6 Netherlands
11.1.7 Switzerland
11.1.8 Belgium
11.1.9 Turkey
11.1.10 Russia
11.1.11 Rest Of Europe
12 Europe Scleroderma Therapeutics Market, Company Landscape
12.1 Company Share Analysis: Europe
13 Company Profiles
13.1 Astrazeneca
13.1.1 Company Snapshot
13.1.2 Revenue Analysis
13.1.3 Geographical Presence
13.1.4 Product Portfolio (Pipeline)
13.1.5 Recent Developments
13.2 F. Hoffmann-la Roche Ltd
13.2.1 Company Snapshot
13.2.2 Reveneue Analysis
13.2.3 Geographical Presence
13.2.4 Product Portfolio
13.2.5 Recent Developments
13.3 Novartis Ag
13.3.1 Company Snapshot
13.3.2 Reveneue Analysis
13.3.3 Geographical Presence
13.3.4 Product Portfolio
13.3.5 Recent Developments
13.4 Pfizer Inc.
13.4.1 Company Snapshot
13.4.2 Reveneue Analysis
13.4.3 Geographical Presence
13.4.4 Product Portfolio
13.4.5 Recent Developments
13.5 Abbvie Inc.
13.5.1 Company Snapshot
13.5.2 Reveneue Analysis
13.5.3 Geographical Presence
13.5.4 Product Portfolio
13.5.5 Recent Developments
13.6 Active Biotech Ab.
13.6.1 Company Overview
13.6.2 Revenue Analysis
13.6.3 Product Portfolio
13.6.4 Recent Development
13.7 Allergan
13.7.1 Company Snapshot
13.7.2 Reveneue Analysis
13.7.3 Geographical Presence
13.7.4 Product Portfolio
13.7.5 Recent Developments
13.8 Argentis Pharmaceuticals, Llc.
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Recent Developments
13.9 Bristol-myers Squibb Company
13.9.1 Company Overview
13.9.2 Revenue Analysis
13.9.3 Geographical Presence
13.9.4 Products Portfolio
13.9.5 Recent Developments
13.10 Daval International Limited
13.10.1 Company Snapshot
13.10.2 Geographical Presence
13.10.3 Product Portfolio
13.10.4 Recent Development
13.11 Glaxosmithkline Plc.
13.11.1 Company Overview
13.11.2 Revenue Analysis
13.11.3 Geographical Presence
13.11.4 Products Portfolio (Pipeline Development)
13.11.5 Recent Development
13.12 Johnson & Johnson Services, Inc.
13.12.1 Company Overview
13.12.2 Revenue Analysis
13.12.3 Geographical Presence
13.12.4 Product Portfolio (Pipeline)
13.12.5 Recent Developments
13.13 Sanofi
13.13.1 Company Snapshot
13.13.2 Reveneue Analysis
13.13.3 Geographical Presence
13.13.4 Product Portfolio
13.13.5 Recent Development
13.14 Vida Therapeutics Inc.
13.14.1 Company Overview
13.14.2 Product Portfolio
13.14.3 Recent Developments
14 Questionnaire
15 Related Reports
List Of Tables
Table 1 Insights About Clinical Trial Phases Of Various Drugs
Table 2 Incidence And Prevalence In Past Decade (Region)
Table 3 Europe Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 4 Europe Systemic Scleroderma In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 5 Europe Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 6 Europe Localized Scleroderma In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 7 Europe Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 8 Europe Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 9 Europe Drug Treatment In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 10 Europe Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 11 Europe Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 12 Europe Surgical Treatment In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 13 Europe Therapy In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 14 Europe Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 15 Europe Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 16 Europe Hospital In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 17 Europe Specialty Clinics In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 18 Europe Homecare Settings In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 19 Europe Others In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 20 Europe Scleroderma Therapeutics Market, By Country, 2017-2026 (Usd Million)
Table 21 Europe Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 22 Europe Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 23 Europe Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 24 Europe Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 25 Europe Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 26 Europe Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 27 Europe Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 28 Europe Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 29 U.K. Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 30 U.K. Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 31 U.K. Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 32 U.K. Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 33 U.K. Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 34 U.K. Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 35 U.K. Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 36 U.K. Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 37 Germany Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 38 Germany Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 39 Germany Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 40 Germany Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 41 Germany Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 42 Germany Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 43 Germany Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 44 Germany Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 45 France Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 46 France Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 47 France Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 48 France Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 49 France Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 50 France Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 51 France Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 52 France Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 53 Spain Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 54 Spain Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 55 Spain Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 56 Spain Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 57 Spain Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 58 Spain Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 59 Spain Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 60 Spain Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 61 Italy Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 62 Italy Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 63 Italy Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 64 Italy Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 65 Italy Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 66 Italy Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 67 Italy Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 68 Italy Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 69 Netherlands Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 70 Netherlands Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 71 Netherlands Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 72 Netherlands Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 73 Netherlands Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 74 Netherlands Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 75 Netherlands Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 76 Netherlands Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 77 Switzerland Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 78 Switzerland Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 79 Switzerland Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 80 Switzerland Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 81 Switzerland Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 82 Switzerland Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 83 Switzerland Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 84 Switzerland Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 85 Belgium Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 86 Belgium Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 87 Belgium Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 88 Belgium Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 89 Belgium Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 90 Belgium Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 91 Belgium Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 92 Belgium Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 93 Turkey Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 94 Turkey Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 95 Turkey Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 96 Turkey Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 97 Turkey Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 98 Turkey Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 99 Turkey Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 100 Turkey Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 101 Russia Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 102 Russia Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 103 Russia Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 104 Russia Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 105 Russia Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 106 Russia Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 107 Russia Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 108 Russia Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 109 Rest Of Europe Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
List Of Figures
Figure 1 Below Is The Scleroderma Map Defining The Types
Figure 2 Europe Scleroderma Therapeutics Market: Segmentation
Figure 3 Europe Scleroderma Therapeutics Market: Data Triangulation
Figure 4 Europe Scleroderma Therapeutics Market: Droc Analysis
Figure 5 Europe Scleroderma Therapeutics Market: Europe Vs Regional Market Analysis
Figure 6 Europe Scleroderma Therapeutics Market: Company Research Analysis
Figure 7 Europe Scleroderma Therapeutics Market: Interview Demographics
Figure 8 Europe Scleroderma Therapeutics Market: Dbmr Market Position Grid
Figure 9 Drivers, Restraints, Opportunities And Challenges Of Europe Scleroderma Therapeutics Market
Figure 10 Europe Scleroderma Therapeutics Market: Segmentation
Figure 11 Rising Cases Of Scleroderma, Increasing Access To Medical Insurance In The U.S., Increasing Merger And Acquisitions Is Expected To Drive The Europe Scleroderma Therapeutics Market In The Forecast Period 2019 To
Figure 12 Systemic Scleroderma Is Expected To Account For The Largest Share Of The Europe Scleroderma Therapeutics Market In 2019 &
Figure 13 Europe Scleroderma Therapeutics Market: By Type ,
Figure 14 Europe Scleroderma Therapeutics Market: By Treatment Type ,
Figure 15 Europe Scleroderma Therapeutics Market: By End User,
Figure 16 Europe Scleroderma Therapeutics Market: Snapshot (2018)
Figure 17 Europe Scleroderma Therapeutics Market: By Country (2018)
Figure 18 Europe Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 19 Europe Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 20 Europe Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 21 Europe Scleroderma Therapeutics Market: Company Share 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report